Editorial correction — October 10, 2026: This essay has been revised to distinguish patient experience, specimen findings, causal hypotheses and treatment evidence. The earlier version overstated the universality of infection and tissue-derived fibers, and drew diagnostic conclusions from treatment response. Those claims have been removed.
The details matter because a confident explanation can change what a patient does next: which clinician they see, which tests they buy, and which treatment they accept. Patient advocacy should make those decisions better informed. It should not require certainty that the research has yet to earn.
People describing Morgellons can face painful lesions, distressing sensations and a difficult search for care. Those experiences deserve attention. A patient’s account is valuable evidence about symptoms and their impact; it is not, by itself, a laboratory identification of a fiber or proof of a shared cause.
Begin with what was actually observed
A lesion, a filament associated with tissue, and loose material presented in a container are not interchangeable findings. Their meaning depends on the examination, collection method, location and laboratory analysis. Describing a specimen carefully is more useful than attaching a conclusion to its color or shape.
In a 2013 four-patient study, investigators described keratin and collagen in selected tissue-associated filaments. They proposed a spirochetal mechanism but acknowledged that the study was too small for definitive conclusions about etiology. A finding about those specimens cannot identify every item submitted by someone using the Morgellons label.
The CDC-led investigation also analyzed material. Its findings included cellulose consistent with cotton and protein likely representing superficial skin. Identifying protein is not equivalent to demonstrating abnormal keratin or collagen production. Equally, identifying cotton in one sample does not determine the identity of all other patients’ samples.
Our histology guide discusses what specimen analysis can establish and where interpretation goes beyond a demonstrated finding.
An association is evidence to investigate, not a universal rule
The 2015 Borrelia study investigated 25 volunteers with clinician-documented skin filaments. Its authors reported Borrelia findings and interpreted them as supporting an infectious explanation. The selected cohort and absence of a matched clinical comparison group limit what can be inferred about causation and the wider population.
A careful critique should acknowledge the laboratory controls used in that study, rather than dismissing it as having no controls at all. A careful defense should also acknowledge that laboratory controls do not substitute for a clinical comparison group.
Finding an organism, proposing a plausible mechanism, and showing that the organism causes a particular clinical syndrome are different steps. Animal findings or experiments in cultured cells can motivate research, but they do not automatically establish a diagnosis or treatment for a person with skin symptoms.
Read the CDC paper in both directions
The CDC-led study identified no common infectious source in its population and described similarities to delusional infestation. It also could not determine whether the presentation was a new condition or broader recognition of an existing one. Presenting only the uncertainty selectively understates its findings; presenting the paper as a psychiatric diagnosis for every future patient overextends them.
The populations and sampling methods differ across this literature. Our comparison of Morgellons studies and closer reading of the CDC paper explain why those differences matter. The first question is whether papers investigated the same kind of presentation, rather than which headline is more reassuring.
Response to treatment is not a diagnostic shortcut
A doxycycline case report described healing while psychiatric medicines continued. A trifluoperazine cohort reported improvement during medication and empathetic counseling without a control group. These reports offer observations about care; they cannot isolate every component of the intervention or settle etiology.
The same standard applies in both directions. Improvement with antibiotics does not automatically prove infection. Improvement with psychiatric medication does not automatically prove that a lesion or sensation had only a psychiatric cause. A patient can also have more than one condition requiring care.
When treatment does not help, the next step is to review the working diagnosis, outcomes, adverse effects and reasons for the result. Declaring every nonresponse proof of misdiagnosis is another shortcut. Declaring every deterioration evidence that treatment is working is one too.
Patient advocacy should leave room for correction
Respectful care can include examining skin findings, evaluating clinically plausible infections, assessing mental health when indicated and managing symptoms while uncertainty remains. These tasks do not have to compete for legitimacy.
A useful article makes its sources traceable and its limits visible. A useful consultation records what was found, why a test or treatment is proposed, and when the plan will be reconsidered. Neither should demand that the patient or clinician settle every controversy before care can begin.
The Clinical Visit Pack and revised clinician letter support that approach. They help bring the conversation back to documented findings, patient priorities and a follow-up plan.